(Q46840686)

25 December 2017

title

Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans (English)

1 reference

25 December 2017

author name string

Nagy A Farid

1

1 reference

25 December 2017

Christopher D Payne

2

1 reference

25 December 2017

C Steven Ernest

3

1 reference

25 December 2017

Y Grace Li

4

1 reference

25 December 2017

Kenneth J Winters

5

1 reference

25 December 2017

Daniel E Salazar

6

1 reference

25 December 2017

David S Small

7

1 reference

25 December 2017

publication date

1 January 2008

1 reference

25 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

25 December 2017

volume

48

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

53-59

1 reference

25 December 2017

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007309709

21 January 2018

Identifiers

DOI

10.1177/0091270007309709

1 reference

25 December 2017

1 reference

25 December 2017